BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is one of the stocks Jim Cramer commented on. A caller asked if the current price is a discount on the company’s rare disease pipeline or if the market has already priced in expectations for the company’s future performance. Cramer replied:
No, no, no, just stay away from that. I mean, honestly, that’s, it is just been a very bad stock for a very long time, and I don’t think it’s going to improve.
A stock market chart. Photo by Arturo A on Pexels
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) sells treatments for rare diseases, including an oral medication for hereditary angioedema and an injectable flu therapy. It also works on discovering and testing new drugs for allergic and immunological conditions. On January 23, the company finalized the $700 million acquisition of Astria Therapeutics. The acquisition adds navenibart to BioCryst Pharmaceuticals, Inc.’s (NASDAQ:BCRX) portfolio. It is a long-acting Phase 3 therapy for hereditary angioedema, which is a rare genetic condition that causes sudden, painful swelling in different parts of the body.
While we acknowledge the potential of BCRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
